Microarray based gene expression profiling of advanced gall bladder cancer

Summary. Background: Gall bladder cancer (GBC) is an aggressive cancer with specific predilection like female gender and specific geographical areas, however the molecular mechanisms and factors contributing to the clinical or biological behavior are not understood. Aim: The aim of this study was to...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2023
Автори: Kumar, A., Gupta, R., Mathur, N., Iyer, V.K., Thulkar, S., Prasad, C.P., Das, P., Rani, L., Maqbool, M., Shukla, N.K., Pal, S., Sundar, D., Sharma, A.
Формат: Стаття
Мова:English
Опубліковано: PH Akademperiodyka 2023
Теми:
Онлайн доступ:https://exp-oncology.com.ua/index.php/Exp/article/view/2020-4-12
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Experimental Oncology

Репозитарії

Experimental Oncology
id oai:ojs2.ex.aqua-time.com.ua:article-157
record_format ojs
institution Experimental Oncology
baseUrl_str
datestamp_date 2023-10-11T16:43:48Z
collection OJS
language English
topic Cdc45
chronic cholecystitis
gall bladder cancer
MCM4
microarray
spellingShingle Cdc45
chronic cholecystitis
gall bladder cancer
MCM4
microarray
Kumar, A.
Gupta, R.
Mathur, N.
Iyer, V.K.
Thulkar, S.
Prasad, C.P.
Das, P.
Rani, L.
Maqbool, M.
Shukla, N.K.
Pal, S.
Sundar, D.
Sharma, A.
Microarray based gene expression profiling of advanced gall bladder cancer
topic_facet Cdc45
chronic cholecystitis
gall bladder cancer
MCM4
microarray
Cdc45
chronic cholecystitis
gall bladder cancer
MCM4
microarray
format Article
author Kumar, A.
Gupta, R.
Mathur, N.
Iyer, V.K.
Thulkar, S.
Prasad, C.P.
Das, P.
Rani, L.
Maqbool, M.
Shukla, N.K.
Pal, S.
Sundar, D.
Sharma, A.
author_facet Kumar, A.
Gupta, R.
Mathur, N.
Iyer, V.K.
Thulkar, S.
Prasad, C.P.
Das, P.
Rani, L.
Maqbool, M.
Shukla, N.K.
Pal, S.
Sundar, D.
Sharma, A.
author_sort Kumar, A.
title Microarray based gene expression profiling of advanced gall bladder cancer
title_short Microarray based gene expression profiling of advanced gall bladder cancer
title_full Microarray based gene expression profiling of advanced gall bladder cancer
title_fullStr Microarray based gene expression profiling of advanced gall bladder cancer
title_full_unstemmed Microarray based gene expression profiling of advanced gall bladder cancer
title_sort microarray based gene expression profiling of advanced gall bladder cancer
title_alt Microarray based gene expression profiling of advanced gall bladder cancer
description Summary. Background: Gall bladder cancer (GBC) is an aggressive cancer with specific predilection like female gender and specific geographical areas, however the molecular mechanisms and factors contributing to the clinical or biological behavior are not understood. Aim: The aim of this study was to perform a comprehensive analysis of differentially expressed genes in advanced GBC and chronic cholecystitis (CC) cases. Materials and Methods: Microarray was planned on fresh specimens of advanced GBC and CC cases using single color cRNA based microarray technique (8X60K format; Agilent Technologies, USA). Twelve advanced GBC and four CC patients were included in the study. Results: Of the total of 1307 differentially expressed genes, 535 genes were significantly upregulated, while 772 genes were significantly downregulated in advanced GBC vs CC samples. Differentially expressed genes were associated with biological processes (55.03%), cellular components (31.48%), and molecular functions (13.49%) respectively. The important pathways or key processes affected were cell cycle, DNA replication, oxidative stress, gastric cancer pathway. Using in silico analysis tools, three differentially expressed genes i.e. TPX2, Cdc45 and MCM4 were selected (for their significant role in DNA replication and microtubule function) and were further validated in 20 advanced GBC cohort by immunohistochemistry. Significant positive association of Cdc45 and MCM4 proteins was found in advanced GBC cases (p = 0.043), suggesting the probable oncogenic role of Cdc45 and MCM4 proteins in advanced GBC. Conclusion: Our data demonstrate the potential regulation of Cdc45-MCM4 axis in advanced GBC tumors. Additionally, our study also revealed a range of differentially expressed genes (e.g. TPX2, AKURA etc.) between GBC and CC, and further validation of these genes might provide a potential diagnostic or therapeutic target in future.
publisher PH Akademperiodyka
publishDate 2023
url https://exp-oncology.com.ua/index.php/Exp/article/view/2020-4-12
work_keys_str_mv AT kumara microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT guptar microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT mathurn microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT iyervk microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT thulkars microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT prasadcp microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT dasp microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT ranil microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT maqboolm microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT shuklank microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT pals microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT sundard microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
AT sharmaa microarraybasedgeneexpressionprofilingofadvancedgallbladdercancer
first_indexed 2025-07-17T12:15:56Z
last_indexed 2025-07-17T12:15:56Z
_version_ 1850411036247588864
spelling oai:ojs2.ex.aqua-time.com.ua:article-1572023-10-11T16:43:48Z Microarray based gene expression profiling of advanced gall bladder cancer Microarray based gene expression profiling of advanced gall bladder cancer Kumar, A. Gupta, R. Mathur, N. Iyer, V.K. Thulkar, S. Prasad, C.P. Das, P. Rani, L. Maqbool, M. Shukla, N.K. Pal, S. Sundar, D. Sharma, A. Cdc45, chronic cholecystitis, gall bladder cancer, MCM4, microarray Cdc45, chronic cholecystitis, gall bladder cancer, MCM4, microarray Summary. Background: Gall bladder cancer (GBC) is an aggressive cancer with specific predilection like female gender and specific geographical areas, however the molecular mechanisms and factors contributing to the clinical or biological behavior are not understood. Aim: The aim of this study was to perform a comprehensive analysis of differentially expressed genes in advanced GBC and chronic cholecystitis (CC) cases. Materials and Methods: Microarray was planned on fresh specimens of advanced GBC and CC cases using single color cRNA based microarray technique (8X60K format; Agilent Technologies, USA). Twelve advanced GBC and four CC patients were included in the study. Results: Of the total of 1307 differentially expressed genes, 535 genes were significantly upregulated, while 772 genes were significantly downregulated in advanced GBC vs CC samples. Differentially expressed genes were associated with biological processes (55.03%), cellular components (31.48%), and molecular functions (13.49%) respectively. The important pathways or key processes affected were cell cycle, DNA replication, oxidative stress, gastric cancer pathway. Using in silico analysis tools, three differentially expressed genes i.e. TPX2, Cdc45 and MCM4 were selected (for their significant role in DNA replication and microtubule function) and were further validated in 20 advanced GBC cohort by immunohistochemistry. Significant positive association of Cdc45 and MCM4 proteins was found in advanced GBC cases (p = 0.043), suggesting the probable oncogenic role of Cdc45 and MCM4 proteins in advanced GBC. Conclusion: Our data demonstrate the potential regulation of Cdc45-MCM4 axis in advanced GBC tumors. Additionally, our study also revealed a range of differentially expressed genes (e.g. TPX2, AKURA etc.) between GBC and CC, and further validation of these genes might provide a potential diagnostic or therapeutic target in future. Summary. Background: Gall bladder cancer (GBC) is an aggressive cancer with specific predilection like female gender and specific geographical areas, however the molecular mechanisms and factors contributing to the clinical or biological behavior are not understood. Aim: The aim of this study was to perform a comprehensive analysis of differentially expressed genes in advanced GBC and chronic cholecystitis (CC) cases. Materials and Methods: Microarray was planned on fresh specimens of advanced GBC and CC cases using single color cRNA based microarray technique (8X60K format; Agilent Technologies, USA). Twelve advanced GBC and four CC patients were included in the study. Results: Of the total of 1307 differentially expressed genes, 535 genes were significantly upregulated, while 772 genes were significantly downregulated in advanced GBC vs CC samples. Differentially expressed genes were associated with biological processes (55.03%), cellular components (31.48%), and molecular functions (13.49%) respectively. The important pathways or key processes affected were cell cycle, DNA replication, oxidative stress, gastric cancer pathway. Using in silico analysis tools, three differentially expressed genes i.e. TPX2, Cdc45 and MCM4 were selected (for their significant role in DNA replication and microtubule function) and were further validated in 20 advanced GBC cohort by immunohistochemistry. Significant positive association of Cdc45 and MCM4 proteins was found in advanced GBC cases (p = 0.043), suggesting the probable oncogenic role of Cdc45 and MCM4 proteins in advanced GBC. Conclusion: Our data demonstrate the potential regulation of Cdc45-MCM4 axis in advanced GBC tumors. Additionally, our study also revealed a range of differentially expressed genes (e.g. TPX2, AKURA etc.) between GBC and CC, and further validation of these genes might provide a potential diagnostic or therapeutic target in future. PH Akademperiodyka 2023-05-30 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2020-4-12 10.32471/exp-oncology.2312-8852.vol-42-no-4.15476 Experimental Oncology; Vol. 42 No. 4 (2020): Experimental Oncology; 277-284 Експериментальна онкологія; Том 42 № 4 (2020): Експериментальна онкологія; 277-284 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-42-no-4 en https://exp-oncology.com.ua/index.php/Exp/article/view/2020-4-12/2020-4-12 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/